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Abstract
Background: WHO recommends starting therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two
nucleoside reverse transcriptase inhibitors (NRTIs), i.e. nevirapine or efavirenz, with lamivudine or emtricitabine, plus
zidovudine or tenofovir. Few studies have compared resistance patterns induced by efavirenz and nevirapine in patients
infected with the CRF01_AE Southeast Asian HIV-subtype. We compared patterns of NNRTI- and NRTI-associated mutations
in Thai adults failing first-line nevirapine- and efavirenz -based combinations, using Bayesian statistics to optimize use of
data.
Methods and Findings: In a treatment cohort of HIV-infected adults on NNRTI-based regimens, 119 experienced virologic
failure (.500 copies/mL), with resistance mutations detected by consensus sequencing. Mutations were analyzed in relation
to demographic, clinical, and laboratory variables at time of genotyping. The Geno2Pheno system was used to evaluate
second-line drug options. Eighty-nine subjects were on nevirapine and 30 on efavirenz. The NRTI backbone consisted of
lamivudine or emtricitabine plus either zidovudine (37), stavudine (65), or tenofovir (19). The K103N mutation was detected
in 83% of patients on efavirenz vs. 28% on nevirapine, whereas Y181C was detected in 56% on nevirapine vs. 20% efavirenz.
M184V was more common with nevirapine (87%) than efavirenz (63%). Nevirapine favored TAM-2 resistance pathways
whereas efavirenz selected both TAM-2 and TAM-1 pathways. Emergence of TAM-2 mutations increased with the duration
of virologic replication (OR 1.25–1.87 per month increment). In zidovudine-containing regimens, the overall risk of resistance
across all drugs was lower with nevirapine than with efavirenz, whereas in tenofovir-containing regimen the opposite was
true.
Conclusions: TAM-2 was the major NRTI resistance pathway for CRF01_AE, particularly with nevirapine; it appeared late
after virological failure. In patients who failed, there appeared to be more second-line drug options when zidovudine was
combined with nevirapine or tenofovir with efavirenz than with alternative combinations.
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Introduction
The World Health Organization (WHO) currently recommends
starting antiretroviral (ARV) combination regimens with a non-
nucleoside reverse transcriptase inhibitor (NNRTI) and two
nucleoside reverse transcriptase inhibitors (NRTIs), i.e. nevirapine
(NVP) or efavirenz (EFV), with lamivudine (3TC) or emtricitabine
(FTC), plus zidovudine (ZDV) or tenofovir (TDF) [1]. The
combination most commonly used in resource limited countries is
a fixed dose formulation containing nevirapine, lamivudine and
either stavudine (d4T) or zidovudine, and efficacy and drug failure
are monitored for most subjects by clinical or, if available, CD4
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two drugs with low genetic barriers to resistance, such as
nevirapine or efavirenz, plus lamivudine as one of the NRTI’s,
poses a risk of accumulation of resistance mutations. This can, in
turn, limit therapeutic drug options for the second-line therapies
[2,3,4,5,6,7,8,9].
In addition the pattern of drug-resistant mutations may differ
according to the particular drug combinations used and the
circulating HIV-1 subtypes. Although a large data base analysis
comparing the NNRTI resistance patterns induced by efavirenz
and nevirapine was recently published [10], there have been few
studies performed in homogeneous groups of patients [11]. With
regard to subtype, in subjects infected with HIV-1 subtype B, the
thymidine analogue mutations pathway 1 or TAM-1 (including
mutations M41L, L210W and T215Y) is probably more frequent
than the TAM-2 pathway (including mutations D67N, K70R,
T215F and K219E/Q) [12,13,14], although systematic studies of
these pathways have not been done. In subtype C virus, Novitsky
and colleagues [15] reported a distinct TAM pathway in patients
failing ZDV/ddI-containing HAART.
Similarly, there may be different pathways for NVP or EFV
resistance mutations which may impact on the success of second
generation NNRTIs. The predominant subtype in Thailand is
CRF01_AE, and there are few published studies analyzing the
resistance mutation patterns that develop during virologic failure
in this important subtype, prevalent throughout East and South-
east Asia [8,16,17,18].
Nationwide access to antiretroviral treatment in Thailand began
in 2002, with gradually increasing coverage to more than 200,000
HIV-infected patients receiving combination antiretroviral drugs,
usually beginning with one of the locally manufactured fixed-dose
combinations, (d4T or ZDV)+3TC+NVP [19]. In case of toxicity,
NVP is replaced by EFV.
The primary objective of this study was to describe and compare
the patterns and frequencies of NNRTI and NRTI-associated
mutations emerging on nevirapine- and efavirenz-based HAART in
Thai HIV-infected adults failing their first-line treatment using
Bayesianstatisticalmethods,withaviewtowardsupportingdecisions
regarding subsequent salvage treatment choices. Secondary objec-
tives were to assess factors associated with more frequent occurrence
of NNRTI and NRTI resistance mutations and to compare clusters
of mutations observed under nevirapine and efavirenz at failure.
Results
Patient characteristics
A total of 138 subjects with virologic failure were identified, 19
of whom (13%) showed neither NNRTI nor NRTI mutations and
were assumed to be non-compliant with their treatment. These 19
were not considered further in this analysis. Of 98 remaining
subjects who initiated a first line nevirapine-based HAART, 10
had nevirapine replaced by efavirenz within 2–4 weeks for toxicity
reasons. Of 21 subjects who initiated efavirenz-based HAART, 1
had efavirenz replaced by nevirapine. Thus, 89 subjects were on
nevirapine- and 30 subjects on efavirenz-based HAART at the
time of virologic failure and showed at least one resistance
mutation. Their demographic, clinical (including NRTI backbone)
and laboratory data at the time of genotyping are described in
Table 1. The estimated length of time from HAART initiation to
virologic failure was about. 220 days and the duration of failure
before genotypic resistance testing was about 90 days; these two
intervals were similar between the 2 groups. D4T and 3TC were
more often used with nevirapine (P,0.001 and P,0.001) while
ZDV, TDF and FTC were more used with efavirenz (P=0.006,
P=0.007 and P=0.001), which supports the need for statistical
adjustments with respect to the NRTI backbone used.
Pattern of resistance mutations
The frequency of NNRTI resistance mutations among the
nevirapine- and efavirenz-based treatment groups is shown in





Age in years 31.4 (28.3–36.5) 32.6 (28.9–37.7) 0.258
Female 81 (91%) 25 (83%) 0.200
CDC stage B or C 30 (34%)(n=88) 13 (46%)(n=28) 0.267
CD4 count (cells/mm3) 241 (173–359) 159 (110–265) 0.005
HIV RNA (log10 copies/mL) 3.70 (3.28–4.09) 3.99 (3.75–4.69) 0.007
CRF01_AE 84 (94%) 29 (97%)
Exposure to single-dose nevirapine 58 (81%) 10 (56%) 0.036
Time (days) from single-dose nevirapine
to HAART initiation
139 (64–397) 387 (125–505) 0.299
ZDV backbone 20(22%) 15(50%) 0.006
d4T backbone 60(67%) 5(17%) ,0.001
TDF backbone 9(10%) 10(33%) 0.007
3TC backbone 82(92%) 19(63%) ,0.001
FTC backbone 7(8%) 10(33%) 0.001
Estimated duration (days) of virologic failure
before HIV resistance genotype testing
91 (42–189) 93 (56–196) 0.743
Time (days) from HAART initiation to
virologic failure
238 (112–609) 212 (88–441) 0.530
All figures are medians (interquartile ranges) or number (percent).
doi:10.1371/journal.pone.0027427.t001
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the NVP-based treatment group, 100% had virus with one or
more NNRTI mutations: Y181C/I was present in 56% (18% as
the sole mutation), G190A/S in 30% (4%) and K103N in 28%
(18%).
Among the efavirenz-based group, 93% had virus with one or
more NNRTI mutation: K103N was present in 83% (32% as the
sole mutation). One fourth of samples had Y181C/I or G190A
mutations.
The K103N (P,0.001) and P225H (P,0.001) mutations were
each significantly more common and Y181C/I (P=0.001),
G190A (P=0.002) and K101Q/E (P=0.003) were each signifi-
cantly less common among subjects failing efavirenz-based treat-
ment as compared to those failing nevirapine-based treatment.
The most prevalent NRTI mutations in both NNRTI groups
were M184V/I (93% in nevirapine and 66% in efavirenz). Four
percent (4 of 89) of the nevirapine-based treatment group and 32%
of the efavirenz-based treatment group had virus with no NRTI
resistance mutations.
Of the nine K65R mutations observed, all were found in
patients on NVP-based treatment, 6 among patients on TDF and
3 among those on d4T.
Number of NRTI and NNRTI resistance mutations
The number of NRTI and NNRTI resistance mutations per subject
was not significantly different between the efavirenz and nevirapine
study subjects. However, tenofovir, when used in the backbone (in
comparison to d4T), was found associated with lower occurrence of
NRTI mutations when combined with efavirenz (OR=0. 58, 90%-
CI=[0.15,1.46], posterior probability (PP)[OR,1]=87%) and higher
occurrence of both NRTI (OR=1.58, 90%-CI=[0.95,2.37],
PP[OR.1]=93%) and NNRTI mutations (OR=1.55, 90%-
CI=[0.94,2.12], PP[OR.1]=93%) when combined with nevirapine.
Zidovudine backbone (also in comparison to d4T) was found
associated with higher occurrence of NRTI mutations when combined
with efavirenz (OR=2.80, 90%-CI=[0.97,6.35], PP[OR.1]=94%).
Longer duration of failure was associated with more frequent
occurrence of NRTI mutations in patients on nevirapine-based
Figure 1. Frequency of resistance mutations observed in subjects failing nevirapine- or efavirenz (EFV)-based treatment. (a) NNRTI
resistance mutations and (b) NRTI resistance mutations observed in 89 subjects failing nevirapine- and 30 failing efavirenz (EFV)-based treatment.
doi:10.1371/journal.pone.0027427.g001
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mutation per additional month on virologic failure (OR=1.05,
90%-CI=[1.02,1.08], PP[OR.1]=99.9%). On average, this
corresponds to one new NRTI resistance mutation every 20
additional months spent in failure.
No strong evidence was found for the effect of viral load at
genotyping. There was also no effect of time to virologic failure.
Model-based analysis, mutation by mutation
Viral load in the first sample after failure, failure duration and
NRTI backbone were the most predictive variables for this analysis.
These variables were selected by the statistical model-building
procedure, which systematically favored random effects instead of
fixed effects models, and were therefore included in the final model
asmutation-specific variables.Timetofailurewas not selected by the
model-buildingprocedureandwashenceexcludedfromtheanalysis.
When adjusted for the effects of failure duration, viral load and
NRTI backbone, the analysis, presented in Figure 2A, showed that
the use ofa nevirapine-based regimen was associated with significantly
increased risks of mutations G190A (the posterior probability of
G190A occurring on a nevirapine-based regimen or PP[OR,1] was
.99%), Y188L (PP[OR,1]=97.5%), Y181C (PP[OR,1].99%),
K101E (PP[OR,1].99%), Y115F (PP[OR,1].99%) and K65R
PP[OR,1].99%) as compared with an efavirenz-based treatment.
A trend towardassociation with M184V(PP[OR,1]=92%) was also
observed. Conversely, the use of an efavirenz-based regimen was
associated with significantly increased risks of the mutations
P225H (PP[OR.1].99%), V106M (PP[OR.1].99%), K103N
(PP[OR.1].99%), L100I (PP[OR.1]=97%), T215Y (PP[OR.1]
=97.5%) and L210W (PP[OR.1].99%). The last two mutations
belong to the TAM-1 pathway.
The NRTI backbone was found to influence the emergence of
some resistance mutations. More specifically, TDF, when
compared with d4T, was found strongly associated with greater
risk of mutations Y115F and K65R (PP[OR.1].99%), and, with
less clear evidence (PP[OR.1].92) with greater risk of mutations
Y181I, V179F, and A62V (Figure 2B). TDF was also associated
with lower risk of mutation M184V (PP[OR,1]=99%) and with
less significance, of mutation V75I (PP[OR,1]=89%). When
ZDV was compared to d4T (Figure 2C), no significant associations
were seen, but in each of the 32 mutations investigated, ZDV
posed a higher risk of mutations, with posterior probabilities up to
80% (Supporting Information S1).
Longer duration of virologic failure was found significantly
associated with higher risk of all TAM-2 mutations (D67N, K70R,
K219Q/E, T215F) and the T215Y mutation with ORs ranging
from 1.25 to 1.84 and PP[OR.1].98% (Figure 2D). Longer
duration of failure was also significantly associated with higher risk
of M184V (PP[OR.1]=94%) and NNRTI mutations G190A
(PP[OR.1]=95%), K101E (PP[OR.1]=94%) and A98G
(PP[OR.1]=99%). Occurrence of K103N was associated with
shorter duration of failure (PP[OR,1]=97%).
Low to moderate evidence (PP[OR.1],80%) was found for
association of viral load at genotyping with higher risk of
mutations, with the single exception of 74V (OR=3.42, 90%-
CI=[0. 97,8.61], PP[OR.1]=94%). Conversely, lower viral
load at genotyping was associated with occurrence of mutation
M184V (OR=0.48, 90%-CI=[0. .22,0.86], PP[OR,1]=98%)
and V108I (OR=0.28, 90%-CI=[0. 06,0.67], PP[OR,1]
=99%).
Cluster analysis
The cluster analysis was performed to identify patterns of
mutation occurrence based on the correlation structure of the
data. The outcomes of the cluster analysis are displayed as
dendrograms in Figure 3. Overall, both NNRTI and NRTI
resistance mutations appear to be substantially less inter-correlated
for efavirenz-based treatment as compared with nevirapine-based
treatment.
In both efavirenz and nevirapine groups, inter-correlations were
weaker for NNRTI (Figure 3A) than for NRTI mutations
(Figure 3B). The cluster D67N-K70R-K219Q-M184V, the first
three of which are in the TAM-2 pathway, contained the NRTI
mutations most likely to occur together in both treatment groups
(Figure 3B). With NVP, the next two mutations, K219E and
T215F, complete the TAM-2 cluster, whereas with EFV, the three
TAM-1 mutations (M41L, L210W, and T215Y) appear next,
along with the K219E from the TAM-2 pathway.
Predicted drug resistance patterns during ARV failure
Based on the measured sequences, the best-predicted phenotype
and a resistance probability score for each drug that might be used
in subsequent treatment were derived using the Geno2Pheno
system [20]. The NRTI backbone (observed at time of failure) was
the only factor, besides NNRTI choice, influencing the resistance
patterns observed on NVP- versus EFV-based regimens, as
evidenced by the model-building process. Figure 4 displays
boxplots showing the WinBUGS-generated posterior distributions
of resistance probabilities for each drug, comparing nevirapine-
based and efavirenz-based HAART, and with NRTI backbones
containing d4T, ZDV or TDF at the time of failure.
Among those in failure while receiving a d4T-containing
backbone (Figure 4A), patients’ viruses were predicted to be
resistant to abacavir (ABC) and 3TC, while they remained
susceptible to d4T, ZDV and TDF whether they had been on
NVP or EFV Likewise, they were quite uniformly resistant to both
NNRTI’s (Supporting Information S2).
With a ZDV-based backbone (Figure 4B), the program
predicted marginally lower resistance to d4T, ZDV and TDF in
those receiving NVP than in those on EFV-based regimens.
Interestingly some susceptibility to EFV persisted in those who had
failed on NVP (Supporting Information S3). With TDF, the
situation showed sharper contrasts (Figure 4C). Those failing on
EFV retained full susceptibility to TDF (zero resistance probabil-
ity), whereas the nevirapine-based HAART group had a 55%
chance to be resistant (Supporting Information S4). Likewise, some
susceptibility was predicted for ABC and 3TC in the EFV-based
group, but little was seen in those failing on NVP. In contrast,
moderate susceptibility to EFV and, to a lesser extent, NVP was
retained by those who failed while on NVP, whereas there was
essentially complete resistance to both drugs in those on EFV-
based regimens.
Discussion
This study, using standard and model-based Bayesian analytic
methods, presents the first detailed comparison of the ARV
resistance patterns found during virologic failure for NVP- vs.
EFV-based combination regimens in a group of subjects infected
with CRF01_AE strains of HIV-1. Our findings emphasize
differences and similarities from the patterns seen during failure
in patients infected with other subtypes.
The clearest differences found between treatment groups were
in specific resistance mutations or clusters rather than in overall
total numbers of mutations. Our analysis offers strong evidence
that, in contrast to the mutation patterns published for other
subtypes [12,13,14,15,21], individuals infected with CRF01_AE
and experiencing virologic failure while receiving NVP-based
HIV Resistance Patterns Selected by NVP vs EFV
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T215F, K219Q/E) rather than TAM-1 (M41L, L210W,
T215Y), whereas those receiving regimens containing EFV appear
to select both TAM-2 and TAM-1 pathways (Figures 1B, 2A and
3B).
As suggested by previous studies of mainly Subtype B viruses
[10,22,23,24,25,26], and as shown in both the raw percentages
(Figure 1A and 1B) and the adjusted Bayesian analysis (Figure 2A),
mutations 101E, 181C and 190A were preferentially selected by
nevirapine, while 103N, 106M, and 225H were preferentially
selected by efavirenz. Wallis, in her study of subtype C, found
similar differential distributions of 101E, 181C, 190A and 106M
but found almost equal proportions of 103N and 225H mutations
selected by EFV and NVP [11]. Reuman et al. also found that
K103N, V106M and P225H were among the 16 NNRTI
mutations preferentially selected by EFV and K101E, Y181C
and G190A among the 12 mutations preferentially selected by
NVP. However, in their analysis of covariation of NNRTI
resistance mutations, the K103N-P225H pair as well the
Y181C-G190A and K101E-Y181C pairs significantly covaried
in sequences from individuals experiencing EFV while the pair
V108I-Y181C covaried in NVP group and the pair K101E-
G190E covaried in both groups [10]. In our study, the pair 101E-
190A of NNRTI mutations was closely correlated only in the
nevirapine group.
Less expected was our finding that the major NRTI mutations
M184V and K65R were preferentially selected in the presence of
nevirapine (Figures 1B and 2A), while TAM-1 mutations were
almost never selected (only in 2% of patients treated by
nevirapine). In contrast, TAM-1 215Y and 210W were preferen-
tially selected in the presence of efavirenz.
The NRTI backbone was shown to influence the resistance
patterns (see Figures 2B and 2C). Our model-based analysis
suggested that tenofovir, in addition to selecting K65R, also
strongly selected Y115F (Figure 2B), a mutation rarely observed in
other subtypes, and then only with the use of a triple-NRTI
regimen [27,28,29]. In contrast, we confirmed the observation that
K65R has an antagonistic effect with TAMs [30], since only 1 of 9
patients in our study had both 65R and one TAM. Also we found
that tenofovir use was associated with a significantly lower rate of
M184V mutation than d4T, illustrated in Figure 2B, while this was
not observed in the 903 study which evaluated the efficacy and
safety of tenofovir vs stavudine when combined with 3TC and
Efavirenz in antiretroviral-naive patients [31]. The trend (seen in
26 of 32 mutations analyzed) towards higher rates of both NRTI
and NNRTI mutations observed with zidovudine in comparison to
d4T (Figure 2C) is consistent with observations by Wallis in South
Africa [11] and Bocket in France [12].
It is likely that the accumulation of mutations resulting in drug
resistance follows specific pathways rather than random sequences.
Duration of virologic failure may be associated with the order of
mutation occurrence, and therefore with the timing of some
mutations. Our analysis, shown in Figure 2D, confirmed that the
M184I mutation occurs before M184V, suggested that K103N is
an early mutation, and showed clearly that all the TAM-2
pathway mutations, as well as 215Y, occur as time spent on
virologic failure increases.
Overall, high viral load at genotyping was not seen to favor
mutation occurrence after failure. Conversely, the clear negative
association of viral load at genotyping and occurrence of
mutations M184V and V108I can be interpreted as an effect of
these mutations on viral fitness. Impairment of HIV fitness in
viruses containing the 184V mutation is well known [32]. There is
one report of lower viral loads with the 108I mutation, and this
analysis confirms that finding [33]. The actual fitness of virus with
this mutation has not been investigated.
In our analysis of resistance and susceptibility to a range of
available drugs, failure on efavirenz-based HAART seemed to
impair any further use of efavirenz and nevirapine, while this was
not systematically the case with nevirapine (Figures 4A–C). The
Geno2Pheno software analysis predicted that resistant virus
selected by nevirapine may still be susceptible to efavirenz and
even, although to a lesser extent, to nevirapine. EFV sensitivity is
likely due to the Y181C mutation, as reported by other groups
[34,35]. The persistent nevirapine susceptibility implies the
possibility that nevirapine may be successfully recycled (perhaps
after the elapse of some time) in resource-constrained environ-
ments. Overall it appears that, in terms of the salvage treatment
options, zidovudine should preferably be associated with nevir-
apine rather than with efavirenz, whereas tenofovir should better
be associated with efavirenz, consistent with the current DHHS
guidelines [36]. The synergistic association of tenofovir and
efavirenz is also supported by the fact that efavirenz was shown
to protect from K65R and Y115F.
One obvious limitation of this analysis is the cross-sectional
nature of the data and methods used. Only one genotype assess-
ment was used per patient so that the dynamics and timing of
resistance mutations could not be investigated. The clusters
identified could therefore not be imputed to some time ordering.
Although the genotype data were of good and consistent quality
as they originated from a single quality-controlled laboratory,
nevertheless, some missing information could alter the precision
and accuracy of some estimates. In addition, the Geno2Pheno pre-
dictions were analyzed as raw data, without accounting for possi-
ble small numbers and any uncertainty in the model since it was
not available on the Max-Planck-Institute Informatik platform.
Finally it should be re-emphasized that our comparative
assessment was made on subjects who had failed their first-line
treatment. Such a study design is less robust than a prospective,
randomized design would have been, but focuses only on events at
Figure 2. Posterior distributions of the log odds ratios of analyzed parameters for each resistance mutation. Median posterior
distributions, 50%- and 90%-credibility intervals are represented. Distributions are based on 1000 simulations using WinBUGS software. In
parentheses are reported the number of patients for which the mutation was observed. A. Distributions of the log odds ratios of efavirenz vs.
nevirapine-based HAART. Points to the left of the zero vertical line indicate a greater frequency of the indicated mutation in NVP-based regimens, and
points to the right of the zero vertical line in EFV-based regimens. B. Distributions of the log odds ratios of tenofovir (TDF) vs. d4T-based backbone.
Points to the left of the zero vertical line indicate a greater frequency of the indicated mutation in d4T-based regimens, and points to the right of the
zero vertical line in TDF-based regimens. C. Distributions of the log odds ratios of zidovudine (ZDV) vs. d4T-based backbone. Points to the left of the
zero vertical line indicate a greater frequency of the indicated mutation in d4T-based regimens, and points to the right of the zero vertical line in ZDV-
based regimens. D. Effect of duration of failure. Distributions of the log odds ratios of one additional month spent on failure. Points to the left of the
zero vertical line indicate a greater frequency of the indicated mutation when failure is one-month shorter, and points to the right when failure is
one-month longer. E. Effect of viral load at genotype. Distributions of the log odds ratios of each resistance mutation for one additional log of HIV
RNA copy/mL. Points to the left of the zero vertical line indicate a greater frequency of the indicated mutation when viral load at genotype is one log
lower, and points to the right when viral load is one log higher.
doi:10.1371/journal.pone.0027427.g002
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similar model-based assessment could be developed on the
population at start of treatment, integrating failure rate and
timing of failure. Such an analysis would be strengthened by the
use of longitudinal data and methods which could provide a
clearer view of resistance mutation pathways over time to support
optimal monitoring and medical decisions throughout treatment.
Nevertheless, our model-based evaluation allowed the compar-
ative assessment of resistance mutation patterns between nevir-
apine-based and efavirenz-based treatment groups, disentangling
the concurrent effects of NRTI backbone and other factors and
accounting for correlations between mutations. The Bayesian tools
enabled the statistical inference of such models and provided
comprehensive outputs and measures of uncertainty attached to
the results. The analysis not only confirmed well-established
patterns already observed in other studies with other subtypes
[8,10,13,22,23,24,25,26,37], but also pointed at less known or new




The study population includes 139 HIV-infected adults enrolled
in the PHPT-GFATM cohort treatment program supported by
the Thai Ministry of Public Health and the Global Fund to Fight
AIDS, Tuberculosis and Malaria (ClinicalTrials.gov Identifier:
NCT00433030). The larger cohort has been described [Fregonese
F, Collins I, Jourdain G, Le Coeur S, Cressey T, Ngo-Giang-
Huong N, Banchongkit S, Chutanunta A, Techapornroong M,
Lallemant M, for the Program for HIV Prevention and Treatment
(PHPT) study group. Survival of HIV-infected Adults Starting
HAART in Thailand: Risk Factors for Early and Long term
Mortality. 18
th Conference on Retroviruses and Opportunistic
Infections, Boston, MA, USA, 2011. Abstract 561]. Subjects were
included in this analysis if they had experienced virologic failure
while on first-line nevirapine- or efavirenz-based HAART and had
genotypic resistance testing before switching to second line
HAART.
At therapy initiation, study subjects were antiretroviral-naı ¨ve
except for prophylaxis of mother-to-child transmission of HIV.
HIV RNA levels and CD4 cell counts were measured at treatment
initiation, three months, six months and every six months
thereafter. Virologic failure was defined as HIV RNA concentra-
tion greater than 500 copies/mL after 6 months of HAART. For
Table 1, the date of virologic failure was defined as the midpoint
between the last viral load ,500 copies/mL and the first viral load
.500 copies/mL. In the model-based analysis, the duration of
virologic failure was estimated taking into account the dates of the
last viral load ,500 copies/mL and the first viral load .500
copies/mL as well as the frequency of blood sampling.
Measurement of plasma HIV-1 RNA
Plasma HIV-1 RNA levels were quantified using the standard
(limit of detection, 400 copies/mL) or the ultrasensitive (limit of
detection, 50 copies/mL) protocol of the Cobas Amplicor HIV-1
Monitor RNA test, version 1.5 (Roche Molecular Systems Inc.,
Branchburg, USA).
Genotypic resistance testing
HIV-1 Resistance testing for the RT gene was performed using
the ViroSeq HIV-1 Genotyping system (Celera Diagnostics,
Alameda, USA) according to the manufacturer’s instructions or
using the consensus technique of the Agence Nationale de
Recherches sur le SIDA (AC11 Resistance Study Group PCR
and Sequencing Procedures http://www.hivfrenchresistance.org/
ANRS-procedures.pdf). The first round of nested PCR was
performed on extracted RNA, with the Kit Titan One tube
(Roche Diagnostics) and the set of MJ3 and MJ4 primers. The
second round PCR used the set of A35 and NEI135 primers. PCR
products were purified using the QIAQUICK Purification PCR
kit (QIAGEN). In both techniques, sequencing products were then
submitted onto the automated genetic analyzer 3100 (Applied
Biosystems, Foster city, CA, USA). Sequences were aligned using
the Viroseq or Seqscape softwares (Applied Biosystems). RT
mutations were identified from the International AIDS Society
USA Drug (IAS-USA) mutation tables, spring 2008 (http://www.
iasusa.org/resistance_mutations): M41L, K65R, D67N, insertion
69, K70R/E, L74I/V, L100I, K103N, V106A/M, V108I,
Q151M, Y181I/C, M184V, Y188C/L, G190A/S, L210W,
T215Y/F, K219Q/E, P225H and M230L. The only additions
to this list since that time are K101H, E138A, and M230L, all
etravirine-associated changes and K101P associated with resis-
tance to NVP, EFV and etravirine. GenBank accession numbers
are HQ996409 to 996529.
Descriptive statistics and demographics
Demographic, laboratory, and clinical characteristics at the time
of genotyping such as CD4 count, HIV RNA, CDC stage, and RT
mutation frequencies were compared between the NVP- and
EFV-based HAART groups. Categorical variables were compared
using Chi-square or Fisher’s exact tests; reported P-values were
two-tailed. Continuous variables were compared using the
Wilcoxon rank-sum test.
Comparison of resistance mutation counts at failure
The total number of NRTI or NNRTI resistance mutations was
compared between the nevirapine and efavirenz groups. In order
to investigate the possible effect of NRTI or NNRTI mutations, a
bivariate binomial-logistic model was fitted to the numbers of
NRTI and NNRTI mutations, accounting for their correlation
using a patient-specific random effect. The logistic regression
component permitted an adjustment for the treatment used
(nevirapine vs. efavirenz and NRTI backbone), failure duration,
time to failure, and the viral load at genotyping.
Mutation-by-mutation analysis
A multivariate logistic regression model was fitted to any NRTI
or NNRTI mutations observed. Covariates considered were
NNRTI treatment (nevirapine or efavirenz), backbone drug
(TDF vs. ZDV vs. d4T), failure duration, viral load at failure,
and time to failure. Those covariates were assumed to have either
mutation-specific effects (random or fixed) or constant effects
across mutations. These choices were based on the performance of
the fitting algorithms (robust convergence) and based on statistical
model selection criteria (Deviance Information Criteria [38],
favoring models which can better reproduce the data observed
Figure 3. Dendrograms showing correlations between resistance mutations for both nevirapine- and efavirenz-based HAART
groups. The distance between clusters is defined as 1-Pearson correlation adjusted for backbone treatment, and failure duration. Smaller distance
indicates greater correlation between mutations (clustering). A. Correlations between NNRTI resistance mutations. B. Correlations between NRTI
resistance mutations. Asterisks (*) and (**) indicate respectively TAM-1 and TAM-2 mutations.
doi:10.1371/journal.pone.0027427.g003
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derived for each of these factors.
Analysis of correlations between resistance mutations
(cluster analysis)
We performed cluster analysis in order to analyze the
multivariate correlation patterns between resistance mutations
observed. The model described in the previous paragraph allowed
the derivation of a correlation matrix of all NRTI and NNRTI
mutations, adjusted for backbone, viral load and duration of
failure effects. Based on this adjustment, a distance, defined as (1 -
correlation), was used to describe the clustering of mutations. The
nearest neighbor algorithm was used as linkage method to
determine in what order clusters may join with each other.
Results are displayed for both NRTI and NNRTI mutations using
a correlation tree or dendrogram, which lists all mutations and
indicates at what level of similarity (or correlation) any two clusters
joined together. The main features of dendrograms for nevirapine-
based and efavirenz-based treatments were then described and
compared.
Phenotype inference
The nucleotide sequences of the region coding for the reverse
transcriptase were submitted to the web-based user interface of the
Max-Planck-Institute Informatik Geno2Pheno website [20]. Based
on the alignment of the uploaded genotype sequence with the
HXB2 reference and on machine learning approaches, the
Geno2Pheno system derives the best-predicted phenotype and a
resistance probability score for a list of drugs. Probability scores
were made available for each viral sequence for the following
antiretroviral drugs: the NRTIs ZDV, ddI, d4T, 3TC, emtricita-
bine (FTC), ABC, and TDF; and the NNRTIs NVP and EFV.
Comparative assessment of drug resistance
For the purpose of modeling, the distributions of Geno2Pheno-
predicted resistance probabilities were dichotomized. The result-
ing binary data were analyzed by a Bernoulli/logistic regression to
compare nevirapine- versus efavirenz-based HAART, with
adjustment for NRTI backbone at failure and with all significant
or relevant covariates included in the model-building phase. Once
the model was fitted to the data, the predictive drug resistance
distributions were compared between efavirenz and nevirapine,
and between the d4T-, ZDV- and TDF-containing backbones.
Bayesian statistical inference and model-building
Bayesian inference was used to fit the statistical models
described above [39]. Briefly, in this framework, prior information
about the quantities of interest was combined with the observed
data to derive a posterior distribution on these quantities, using
Monte Carlo Markov chains algorithms. In all analyses, only non-
informative priors were used. Bayesian inference is appropriate for
mixed-effect and/or non linear models like the ones used,
especially in the case of small sample sizes [39,40]. The 90%-
credibility interval (CI) attached to point estimates are presented
and can be directly interpreted as the range within which there is
90% chance that the quantity of interest lies.
Point estimates were reported as mean posterior estimates. For
odds ratios estimates, their (posterior) probability to be greater
than 1 (PP[OR.1]) or lower than 1 (PP[OR,1]) was reported in
addition to credibility intervals. To visualize posterior distribu-
tions, posterior medians, inter-quartile ranges, and 90%-credibility
intervals were presented as boxplots using ad hoc routines coded in
Matlab Release 14.
The model-building phase was consistently implemented as
follows. First, the model was fitted to the data without any
covariate. Then, the resulting estimates were used as initial values.
The WinBUGS software (version 1.4, [41]) was used for both the
assessment of the model-building and the final models.
Supporting Information
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Supporting Information S2 Resistance probabilities with a
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